![Frontiers | Individualized Dosing With High Inter-Occasion Variability Is Correctly Handled With Model-Informed Precision Dosing—Using Rifampicin as an Example Frontiers | Individualized Dosing With High Inter-Occasion Variability Is Correctly Handled With Model-Informed Precision Dosing—Using Rifampicin as an Example](https://www.frontiersin.org/files/Articles/512473/fphar-11-00794-HTML/image_m/fphar-11-00794-g001.jpg)
Frontiers | Individualized Dosing With High Inter-Occasion Variability Is Correctly Handled With Model-Informed Precision Dosing—Using Rifampicin as an Example
![Session 1: An Introductory Workshop in Population PK/PD Data Analysis with NONMEM® (In Person) - School of Pharmacy and Pharmaceutical Sciences - University at Buffalo Session 1: An Introductory Workshop in Population PK/PD Data Analysis with NONMEM® (In Person) - School of Pharmacy and Pharmaceutical Sciences - University at Buffalo](https://pharmacy.buffalo.edu/content/pharmacy/news-events/events/annual-events/pharmaco-courses/population-pkpd-analysis/_jcr_content/par/image.img.219.auto.jpg/1666814823792.jpg)
Session 1: An Introductory Workshop in Population PK/PD Data Analysis with NONMEM® (In Person) - School of Pharmacy and Pharmaceutical Sciences - University at Buffalo
![Prior information for population pharmacokinetic and pharmacokinetic/pharmacodynamic analysis: overview and guidance with a focus on the NONMEM PRIOR subroutine | SpringerLink Prior information for population pharmacokinetic and pharmacokinetic/pharmacodynamic analysis: overview and guidance with a focus on the NONMEM PRIOR subroutine | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs10928-020-09695-z/MediaObjects/10928_2020_9695_Fig2_HTML.png)
Prior information for population pharmacokinetic and pharmacokinetic/pharmacodynamic analysis: overview and guidance with a focus on the NONMEM PRIOR subroutine | SpringerLink
![Pharmacokinetics and population pharmacokinetics in pediatric oncology - Sassen - 2020 - Pediatric Blood & Cancer - Wiley Online Library Pharmacokinetics and population pharmacokinetics in pediatric oncology - Sassen - 2020 - Pediatric Blood & Cancer - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/ffe04924-fb8c-467d-9db0-5acd962121d7/pbc28132-fig-0003-m.jpg)
Pharmacokinetics and population pharmacokinetics in pediatric oncology - Sassen - 2020 - Pediatric Blood & Cancer - Wiley Online Library
![Fitusiran Population Pharmacokinetic and Pharmacodynamic (PopPK/PD) Modeling to Support Revised Dose, Dosing Regimens & Dose Mitigation Scheme - ISTH Congress Abstracts Fitusiran Population Pharmacokinetic and Pharmacodynamic (PopPK/PD) Modeling to Support Revised Dose, Dosing Regimens & Dose Mitigation Scheme - ISTH Congress Abstracts](https://abstracts.isth.org/wp-content/uploads/2021/06/732_conclusions_1.jpg)
Fitusiran Population Pharmacokinetic and Pharmacodynamic (PopPK/PD) Modeling to Support Revised Dose, Dosing Regimens & Dose Mitigation Scheme - ISTH Congress Abstracts
![Pharmaceutics | Free Full-Text | Matrix Effects of the Hydroethanolic Extract of Calyces of Physalis peruviana L. on Rutin Pharmacokinetics in Wistar Rats Using Population Modeling Pharmaceutics | Free Full-Text | Matrix Effects of the Hydroethanolic Extract of Calyces of Physalis peruviana L. on Rutin Pharmacokinetics in Wistar Rats Using Population Modeling](https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-13-00535/article_deploy/html/images/pharmaceutics-13-00535-ag-550.jpg?1628125543)
Pharmaceutics | Free Full-Text | Matrix Effects of the Hydroethanolic Extract of Calyces of Physalis peruviana L. on Rutin Pharmacokinetics in Wistar Rats Using Population Modeling
![A Novel Integrated Pharmacokinetic-Pharmacodynamic Model to Evaluate Combination Therapy and Determine In Vivo Synergism | Journal of Pharmacology and Experimental Therapeutics A Novel Integrated Pharmacokinetic-Pharmacodynamic Model to Evaluate Combination Therapy and Determine In Vivo Synergism | Journal of Pharmacology and Experimental Therapeutics](https://jpet.aspetjournals.org/sites/default/files/highwire/jpet/377/3.cover-source.jpg)
A Novel Integrated Pharmacokinetic-Pharmacodynamic Model to Evaluate Combination Therapy and Determine In Vivo Synergism | Journal of Pharmacology and Experimental Therapeutics
![Population Pharmacokinetics of an Anti-PD-1 Antibody Camrelizumab in Patients with Multiple tumor types and model informed dosing strategy | bioRxiv Population Pharmacokinetics of an Anti-PD-1 Antibody Camrelizumab in Patients with Multiple tumor types and model informed dosing strategy | bioRxiv](https://www.biorxiv.org/content/biorxiv/early/2020/07/02/2020.06.30.180117/F3.large.jpg)
Population Pharmacokinetics of an Anti-PD-1 Antibody Camrelizumab in Patients with Multiple tumor types and model informed dosing strategy | bioRxiv
![Simulation results using PK parameters obtained from PopPK analysis... | Download Scientific Diagram Simulation results using PK parameters obtained from PopPK analysis... | Download Scientific Diagram](https://www.researchgate.net/publication/344370348/figure/fig4/AS:960059009941537@1605907313652/Simulation-results-using-PK-parameters-obtained-from-PopPK-analysis-versus-observed.png)
Simulation results using PK parameters obtained from PopPK analysis... | Download Scientific Diagram
![Combining “Bottom‐up” and “Top‐down” Approaches to Assess the Impact of Food and Gastric pH on Pictilisib (GDC‐0941) Pharmacokinetics - Lu - 2017 - CPT: Pharmacometrics & Systems Pharmacology - Wiley Online Library Combining “Bottom‐up” and “Top‐down” Approaches to Assess the Impact of Food and Gastric pH on Pictilisib (GDC‐0941) Pharmacokinetics - Lu - 2017 - CPT: Pharmacometrics & Systems Pharmacology - Wiley Online Library](https://ascpt.onlinelibrary.wiley.com/cms/asset/ad005f80-dc25-46ab-9a47-c326a24d6e98/psp412228-fig-0003-m.jpg)
Combining “Bottom‐up” and “Top‐down” Approaches to Assess the Impact of Food and Gastric pH on Pictilisib (GDC‐0941) Pharmacokinetics - Lu - 2017 - CPT: Pharmacometrics & Systems Pharmacology - Wiley Online Library
![A Survey of Population Pharmacokinetic Reports Submitted to the USFDA: An Analysis of Common Issues in NDA and BLA from 2012 to 2021 | SpringerLink A Survey of Population Pharmacokinetic Reports Submitted to the USFDA: An Analysis of Common Issues in NDA and BLA from 2012 to 2021 | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40262-022-01182-7/MediaObjects/40262_2022_1182_Fig1_HTML.png)
A Survey of Population Pharmacokinetic Reports Submitted to the USFDA: An Analysis of Common Issues in NDA and BLA from 2012 to 2021 | SpringerLink
![Establishing Best Practices and Guidance in Population Modeling: An Experience With an Internal Population Pharmacokinetic Analysis Guidance - Byon - 2013 - CPT: Pharmacometrics & Systems Pharmacology - Wiley Online Library Establishing Best Practices and Guidance in Population Modeling: An Experience With an Internal Population Pharmacokinetic Analysis Guidance - Byon - 2013 - CPT: Pharmacometrics & Systems Pharmacology - Wiley Online Library](https://ascpt.onlinelibrary.wiley.com/cms/asset/bfa93ba2-7aef-4a83-ac49-d43a9ad90fc6/psp4201326-fig-0002-m.jpg)
Establishing Best Practices and Guidance in Population Modeling: An Experience With an Internal Population Pharmacokinetic Analysis Guidance - Byon - 2013 - CPT: Pharmacometrics & Systems Pharmacology - Wiley Online Library
![Population Pharmacokinetic Variables: THETA, ETA, EPSILON; and NONMEM for analysis - Pharmacoengineering Population Pharmacokinetic Variables: THETA, ETA, EPSILON; and NONMEM for analysis - Pharmacoengineering](https://i2.wp.com/www.pharmacoengineering.com/wp-content/uploads/2020/09/image-54.png?resize=579%2C363&ssl=1)
Population Pharmacokinetic Variables: THETA, ETA, EPSILON; and NONMEM for analysis - Pharmacoengineering
![Pharmacokinetic–pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies | British Journal of Cancer Pharmacokinetic–pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41416-021-01444-4/MediaObjects/41416_2021_1444_Fig1_HTML.png)